INTRODUCTION
Over the past decades, excipient suppliers have developed novel mixtures and new physical forms of excipients that are tailored to the needs of newer delivery platforms (transdermal, pulmonary, oral modified release). Most excipient manufacturers however concentrate on modifying existing excipients as opposed to developing entirely new ones. This is so because regulatory restrictions have made innovation rather difficult. Under US law, an excipient cannot be sold for use in approved drugs unless it can be qualified through one or more of the three FDA approval mechanisms.These include determination by FDA that the substance is "generally recognized as safe" (GRAS), is approved through a food additive petition, or is referenced in an approved new drug application (NDA) for a particular function in that specific drug product.
The International Pharmaceutical Excipients Council (IPEC) spells out 13 general categories of excipients for solid dosage forms based on function: binders, disintegrants, fillers, lubricants, glidants, compression aids, colors, sweeteners, preservatives, suspending /dispersing agents, film formers/coatings, flavors, and printing inks. This Update paper cites a few examples, where novel excipients or existing excipients in novel roles caused a significant improvement in product performance.
EXCIPIENT SYNERGIES AND MULTIFUNCTIONALITY:

Improving Flowability
Today, it is not unheard of to have tableting equipment compressing 8,000 to 10,000 tablets per minute. It is critical under these conditions to have an excellent flowing granulation/powder blend. Many sugar-based excipients, such as maltose, mannitol, and sorbitol are not compressible in their natural state and need to be modified for use in direct compression tableting.
Advantose
TM 100 maltose powder (SPI Polyols) is a disaccharide carbohydrate, with flow and tableting properties that are greatly improved by the process of spray drying. Spray-dried Advantose TM 100 particles are spherical with an optimal combination of fine and coarse particles that contributes to superior flow. When compared to microcrystalline cellulose (MCC), spray-dried maltose can tolerate significantly greater compression forces (>4000 lb) without capping upon ejection from the tableting die. It also exhibits lower hygroscopicity and lower reactivity; thus providing more stable tablets as compared to those made with MCC.
Formulating a High-Dose Active Formulation
Formulations prepared using a high concentration of active or multiple actives pose challenges, such as segregation of powder blends, low content uniformity, and poor flow. Such formulations require excessive amounts of conventional binders, such as MCC and dicalcium phosphate (DCP) to achieve workable compactibility. Maintaining tablet size then becomes an additional cause of concern.
ProSolv SMCC TM (Penwest Pharmaceuticals) is a patented combination of MCC and colloidal silicon dioxide (CSD), known to work together synergistically to optimize product performance. Formulating with ProSolv SMCC TM has been shown to reduce binder usage by more than half, cutting tablet size consequently. Hence, it is ideally suited to highdose direct-compression formulations in which it has advantages in both flow and compactibility over conventional MCC.
Dealing with difficult actives
Many new drug candidates exhibit poor solubility and stability. Excipient compatibility is another issue with some of these compounds. Furthermore, some macromolecular peptide and protein drugs need to be protected and delivered safely through the gastrointestinal tract to the site of most active absorption.
Formulating a Moisture-Sensitive Active
Corn starch has long been used as disintegrate in oral solid dosage forms. Physical modifications of corn starch, through partial pregelatinization (Starch 1500 TM , Colorcon) have added functional benefits in terms of flowability and lubricity, while retaining its disintegrant capability and moisture stability.
Superdisintegrants function primarily by drawing large amounts of water into the tablet while simultaneously swelling. It is this great affinity for water that can impact the stability of moisture-sensitive materials under accelerated storage conditions. Partially pregelatinized starchhas been shown to exhibit a lower propensity for moisture, thus providing excellent stabilization of formulations.
Formulating a Poorly Soluble Active
Almost 10% of currently marketed drugs are poorly soluble. Almost 40% of new chemical entities (NCE) are dropped due to solubility issues. Poor water solubility leads to poor dissolution kinetics and suboptimal bioavailability. NanoCrystal® (Elan Pharmaceuticals) and NanoEdge® (Baxter Healthcare) technologies involve decreasing the particle size of actives to nanometer size range, thus leading to an increase in the surface area and a subsequent increase in dissolution rate. These drug particles are stabilized against agglomeration by surface adsorption of selected proprietary GRAS excipients, such as ionic surfactants and block copolymers. The result is a colloidal dispersion, which can later be freeze dried or spray dried to yield nanoparticles in the 500-nm range. This is an attractive option for actives with high toxicity and low potency.
Formulating a Poorly Absorbed Active
Another major hurdle to effective oral drug delivery in humans is poor absorption of drugs through the epithelial membrane. Biopharmaceutical studies have shown that vitamin E TPGS TM (a-tocopheryl PEG 1000 succinate, Eastman Chemical Company) can be used as a safe and effective absorption enhancer for poorly absorbed drugs, such as cyclosporine and protease inhibitors. It functions so by enhancing the solubility and permeability of drugs.
Working Around Drug-Excipient Incompatibility
Excipients can interact with drugs in the solid state by: acting as a moisture source, providing surface contact points, lowering the drug melting point by forming a eutectic mixture, and acting as a reaction catalyst or chemical reactant. DI-TAB TM (dicalcium phosphate, Rhodia) is a directly compressible filler-binder that contains "mobile" water of crystallization. These water molecules can be transferred to other components in the formulation during tableting or aging. Rhodia has taken this established product and developed a product called A-TAB TM , anhydrousdicalcium phosphate. A-TAB TM is very stable at high temperatures and humidities, thus stabilizing the formulation.
One of the more common drug-excipient incompatibilities is the reaction between aldehydic sugars, such as lactose and primary and secondary amines, leading to the formation of Schiff's bases. These complex series of reactions lead to browning and discoloration of the dosage form. Despite being a carrier of choice for dry powder aerosol formulations, lactose may need to be replaced with a different carrier, such as mannitol or sucrose, when formulating primary and secondary amines (eg, tobramycin).
Formulating Peptides/Proteins
Progress in the development of peptides as useful drugs has been impeded in part by their rapid excretion, resulting in short circulating lifetimes. This generated considerable interest in improving the duration of action of drugs through conjugation with the water-soluble, biocompatible excipient, poly(ethylene glycol). Such conjugates have reduced enzymatic degradation rates and lengthened circulating lifetimes compared to the native compounds.
Other novel lipophilic carbohydrate excipients, termed oligosaccharide ester derivatives (OEDs), have been used to modify pharmacokinetic profiles of drugs. This technology is quite flexible, offering the ability to formulate drug molecules with modified-release characteristics and improved bioavailability. Another technology from the same company makes use of select carbohydrate excipients, such as trehalose and sucrose to stabilize molecules in the dry state, thereby preventing their physical and chemical degradation at ambient temperatures and above. These patent-protected drug delivery technologies are suited to the delivery of macromolecules, such as proteins and peptides by the pulmonary, oral, and injectable routes. 
REGULATORY REQUIREMENT
Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. In the US, it is the function of the Food and Drug Administration (FDA) to establish these regulatory requirements. The European Medicines Agency (EMEA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) are also important regulatory authorities in drug development. These three agencies oversee the three largest markets for drug sales.
Historically, the various regulatory authorities have had their own methods for obtaining regulatory approval, however the rising cost of meeting the demands of differing regulations led to the establishment of an International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in an attempt to co-ordinate and synthesize international regulatory requirements. The first Conference was held in Brussels in 1991, followed by ICH 2 in Orlando, Florida in 1993, and ICH 3 in Yokohama, Japan in 1995. The Fourth International Conference on Harmonisation, in July 1997, was once again in Brussels.
These systems of new drug approvals are extremely rigorous and costly. On average, it will cost a pharmaceutical company $359 million to get one new medicine from the laboratory to the pharmacist's shelf, according to a February 1993 report by the Congressional Office of Technology Assessment. It takes 12 years on average for an experimental drugto travel from the laboratory to the medicine chest. Only five in 5,000 compounds that enter preclinical testing will actually progress into human clinical trials, and of these five, only one is likely to be approved by the regulatory authorities. 
Poly (amidoamide)dendrimers
Such polymers containing one or more types of membrane-targeting antimicrobial agents immobilized on a substrate with activity in relevant biological environments, and methods of making and using thereof, are described herein. The antimicrobial agents retain their activity in the presence of blood proteins and/or in vivo due to improved molecular structures which allow for cooperative action of immobilized agents and hydrophilic chemistries which resist non-specific protein adsorption. Suitable molecular structures include branched structures, such as dendrimers and randomly branched polymers. The molecule structures may also include hydrophilic tethers which provide both flexibility and resistance to non-specific protein adsorption. The membrane targeting antimicrobial agent coatings can be applied to a variety of different types of substrates including medical implants such as vascular grafts, orthopedic devices, dialysis access grafts, and catheters; surgical tools, surgical garments; and bandages. The substrates can be composed of metallic materials, ceramics, polymers, fibers, inert materials such as silicon, and combinations thereof. The compositions described herein are substantially nonleaching, resistant to non-specific protein adsorption, and non-hemolytic.
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Poly (L-lactide)-poly (oxyethylene)-poly (L-lactide)
Such block copolymers obtained in bulk, by a ring opening mechanism, from poly (ethylene glycol)s (PEG)s and L-lactide (LA), at 120-140°C, in the absence of added catalysts are described. By using PEGs with different molecular masses, 3000 and 35000, respectively, and varying the initial molar ratio LA to PEG, two series of copolymers with different molecular masses, relative length of blocks and hydrophilicity were obtained.
The morphological characteristics of the copolymers were investigated by means of X-ray diffractometry, optical and scanning electron microscopy. The biological properties of the materials were determined by evaluating their cytotoxicity, cytocompatibility, hemocompatibility and degradability using different standard tests. The results obtained indicate that the block copolymers synthesized may be useful for biomedical applications, in particular as restorable drug vehicles. The materials are brittle and their mechanical properties are not appropriate for implant devices.
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Poly(fumaric-co-sea-basic) Sea-basic acids are better candidates for bioadhesive delivery systems since, as hydrolysis proceeds, causing surface erosion, more and more carboxylic groups are exposed to the external surface. However, polylactides erode more slowly by bulk erosion.
In designing bioadhesive polymeric systems based on polylactides, polymers that have high concentrations of carboxylic acid are preferred. This can be accomplished Polyacrylamide microspheres were produced by polymerizing an aqueous emulsion of acrylamide and bismethacrylamide in hexane.. This working solution was extensively degassed under water vacuum to remove dissolved oxygen which might inhibit the polymerization reaction.
Route of administration
It requires Gene transfer in humans as carriers for the plasmid DNA which can efficiently and safely carry the gene into the nucleus of the desired cells. A series of chemically different cationic polymers are currently being investigated for these purposes. Although many cationic polymers indeed condense DNA spontaneously, which is a requirement for gene transfer in most types of cells, the physicochemical and biopharmaceutical behavior of the current generation of polyp lexes severely limits an efficient gene transfer in vitro and especially in vivo.
This summarizes recent physicochemical and biological information on polyp lexes and aims to provide new insights with respect to this type of gene delivery system. Firstly, the chemical structure of frequently studied cationic polymers is represented. Secondly, the parameters influencing condensation of DNA by cationic polymers are described. Thirdly, the surface properties, solubility, aggregation behavior, degradation and dissociation of polyplexes are considered. The review ends by describing the in vitro and in vivogenetransfection behavior of polyplexes.
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The Steryl (polylysine) It requires Gene transfer in humans as carriers for the plasmid DNA which can efficiently and safely carry the gene into the nucleus of the desired cells. A series of chemically different cationic polymers are currently being investigated for these purposes. Although many cationic polymersindeed condense DNAspontaneously, which is a requirement for gene transfer in most types of cells, the physicochemical and biopharmaceutical behavior of the current generation of polyp lexes severely limits an efficient gene transfer in vitro and especially in vivo.
This summarizes recent physicochemical and biological information on polyp lexes and aims to provide new insights with respect to this type of gene delivery system. Firstly, the chemical structure of frequently studied cationic polymers is represented. Secondly, the parameters influencing condensation of DNA by cationic polymers are described. Thirdly, the surface properties, solubility, aggregation behavior, degradation and dissociation ofpolyplexes are considered. The review ends by describing the in vitro and in vivogenetransfection behavior of polyp lexes.
It relates to the delivery of desired compounds (e.g., nucleic acids) into cells using releasable delivery systems which include complexing nucleic acids and delivery ligands and used in the following applications as in Gene Therapy and Nucleic Acid, Polymers for Drug and Nucleic Acid Delivery, Condensation template polymerization of DNA, Endosome Diruption and Gene Expression.
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Polyaspartic acid (PASP), (A metal corrosion inhibitor), biodegradable and environment friendly, is a kind of green chemicals of demand increasing globally. The synthesis and application of PASP is popular in many countries because the problem of environment has been paid more and more attention. The field of PASP application is not same with different molecular weight range.
Properties:
PASP can be used as scale and corrosion inhibitor in industrial circulating cool water system, boiler water, reverse osmosis, oilfield water and desalination plant. The effects will be even better than ordinary organophosphines. When used in situation of high hardness, high alkaline, high pH value and high concentration index. When built with PBTCA, the synergism is obvious.
As a metal corrosion inhibitor, PASP has good corrosion inhibition ability with pH>10 and it also has good corrosion inhibition ability with low concentration for sea water. When built with organ phosphor, sodium tungstate, quatenary ammonium salt, zinc salt, molybdate, oxidized starch, and so on, the synergism is obvious.
As a nutrient absorption enhancer, PASP can be used in agriculture. When PASP is applied to fertilizer, it can enhance the availability of N, P, and K resulting in increased yields because of its high capacity for chelating metal ions.
As a new polymer, PASP can be reacted with cross linker into superabsorbent agent. This product with properties of non-pollution and fully biodegradation can be used for hygiene products.
